DULCOLAX
Sanofi, Boehringer Ingelheim seek CCI nod for $25-billion global asset swap dealThe commission will review if the two companies swapping their businesses will cause any adverse impact on the local competition.
Zydus Cadila loses two popular brandsDulcolax and Buscopan had been present for the past many decades in India, initially through an agreement that Boehringer Ingelheim had wit...- German pharma company Boehringer Ingelheim remains bullish on R&D and India"I am quite convinced that as more and more Indian generic companies start doing their own research, I think it will change the conditions ...
- Load More